JR Pharma Engineering Holding ApS: Financial statements 2025
CVR: 42396273
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
JR Pharma Engineering Holding ApS (CVR 42396273) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 601,978 compared with DKK 649,533 the year before. Equity in the 2025 report amounted to DKK 2,451,971. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 601,978
- Equity
- DKK 2,451,971
- Total Assets
- DKK 2,451,971
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 0 | 0 | 602 t. | 2.5 mio. | 0 |
| 2024 | 0 | 0 | 650 t. | 1.8 mio. | - |
| 2023 | 0 | 0 | 1.2 mio. | 1.2 mio. | - |
Official annual report
How creditworthy is JR Pharma Engineering Holding ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout JR Pharma Engineering Holding ApS
JR Pharma Engineering Holding ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2021. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Jimmy Rønne Jensen. The company is owned by Jimmy Rønne Jensen. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported a gross profit of DKK 554,386 and a net result of DKK 560,509 compared with DKK 601,978 the year before. Equity in the 2026 report amounted to DKK 3,012,480.